BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
So those patients were randomized and this trial was designed a while ago where there was really no treatment for these patients in the adjuvant setting, especially if they couldn't receive cisplatin and base chemotherapy, either neoadjuvant or adjuvant setting. The patients were randomized to receive pembrolizumab for one year versus observation.
0
💬
0
Comments
Log in to comment.
There are no comments yet.